| Date of Abstract presentation | 10th December 2023 |
| Indications | Follicular Lymphoma |
| Abstract Number | 3026 |
| Abstract type | Oral |
According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Additionally, the median duration of response (DOR) reached 5.5 months during the study’s median follow-up period of 18.4 months. At the 16.8-month mark, the median progression-free survival (PFS) was calculated to be 5.8 months. Noteworthy is the fact that the median overall survival (OS) could not be estimated (NE) as of the 20.4-month median follow-up.
In terms of safety, the most frequent grade ≥3 treatment-emergent adverse events (TEAEs) were infection, observed in 18.8% of cases (n=9), and neutropenia or decreased neutrophil count, reported in 14.6% of instances (n=7). Notably, only one patient (2.1%) experienced a treatment-related adverse event, specifically a rash, leading to the discontinuation of pirtobrutinib.
KOL insights
“FL is a chronic, indolent, and incurable disease with frequent relapses. Unfortunately, survival outcomes decrease with each subsequent line of treatment. “There have been some data looking at the role of covalent BTK inhibitors in relapsed/refractory FL; however the single-agent efficacy is overall limited, with an ORR of approximately 20% to 38%. We [accordingly explored] pirtobrutinib, a non-covalent BTK inhibitor, for patients with relapsed/refractory FL.” –Expert Opinion.
Conclusion
The administration of pirtobrutinib as a standalone treatment demonstrated promising effectiveness and a manageable safety profile among a group of extensively treated individuals grappling with R/R FL. These findings indicate that pirtobrutinib could serve as a clinically relevant and valuable option for patients contending with R/R FL, offering a potential avenue for effective therapeutic intervention in this challenging clinical context.
Refer to the Related Reports for More In-depth Insights –
-Agonist.png "Toll-like Receptors Agonist")
